BR112022006259A2 - Polimorfos de composto antifíngico de triazol pc945 - Google Patents

Polimorfos de composto antifíngico de triazol pc945

Info

Publication number
BR112022006259A2
BR112022006259A2 BR112022006259A BR112022006259A BR112022006259A2 BR 112022006259 A2 BR112022006259 A2 BR 112022006259A2 BR 112022006259 A BR112022006259 A BR 112022006259A BR 112022006259 A BR112022006259 A BR 112022006259A BR 112022006259 A2 BR112022006259 A2 BR 112022006259A2
Authority
BR
Brazil
Prior art keywords
antifungal compound
triazole antifungal
polymorphs
compound polymorphs
triazole
Prior art date
Application number
BR112022006259A
Other languages
English (en)
Portuguese (pt)
Inventor
John Wallis Christopher
Gerald Steele
Jamie Marshall
John Mykytiuk
Julian Northen
Osama Suleiman
Suzanne Buttar
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Publication of BR112022006259A2 publication Critical patent/BR112022006259A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022006259A 2019-12-06 2020-12-04 Polimorfos de composto antifíngico de triazol pc945 BR112022006259A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1917867.2A GB201917867D0 (en) 2019-12-06 2019-12-06 Polymorphs
PCT/GB2020/053107 WO2021111142A1 (en) 2019-12-06 2020-12-04 Polymorphs of triazole antifungal compound pc945

Publications (1)

Publication Number Publication Date
BR112022006259A2 true BR112022006259A2 (pt) 2022-06-21

Family

ID=69171938

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022006259A BR112022006259A2 (pt) 2019-12-06 2020-12-04 Polimorfos de composto antifíngico de triazol pc945

Country Status (26)

Country Link
US (2) US12491182B2 (cg-RX-API-DMAC7.html)
EP (2) EP4069690B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023505227A (cg-RX-API-DMAC7.html)
KR (1) KR20220110726A (cg-RX-API-DMAC7.html)
CN (1) CN114746415B (cg-RX-API-DMAC7.html)
AU (1) AU2020397613A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006259A2 (cg-RX-API-DMAC7.html)
CA (1) CA3155829A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001464A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022007808A2 (cg-RX-API-DMAC7.html)
DK (1) DK4069690T3 (cg-RX-API-DMAC7.html)
ES (1) ES3000984T3 (cg-RX-API-DMAC7.html)
FI (1) FI4069690T3 (cg-RX-API-DMAC7.html)
GB (1) GB201917867D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250042T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069799T2 (cg-RX-API-DMAC7.html)
IL (1) IL293401B1 (cg-RX-API-DMAC7.html)
LT (1) LT4069690T (cg-RX-API-DMAC7.html)
MX (1) MX2022006654A (cg-RX-API-DMAC7.html)
PL (1) PL4069690T3 (cg-RX-API-DMAC7.html)
PT (1) PT4069690T (cg-RX-API-DMAC7.html)
RS (1) RS66401B1 (cg-RX-API-DMAC7.html)
SA (1) SA522432879B1 (cg-RX-API-DMAC7.html)
SI (1) SI4069690T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400514T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021111142A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016087880A1 (en) 2014-12-05 2016-06-09 Pulmocide Limited Antimycotic compound
CN117510488B (zh) * 2022-07-28 2025-12-05 博瑞制药(苏州)有限公司 一种硫酸艾沙康唑的制备方法
CN117330660A (zh) * 2023-09-14 2024-01-02 广州医科大学附属第一医院(广州呼吸中心) Uplc-ms/ms联用检测艾沙康唑的方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
AU2811689A (en) 1987-11-20 1989-06-14 Schering Corporation Tri-and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
DK0736030T3 (da) 1993-12-21 2001-10-29 Schering Corp Fungicide tetrahydrofuraner
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2199291T3 (es) 1995-06-02 2004-02-16 Schering Corporation Antifungicos de tetrahidrofurano.
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
PL212985B1 (pl) 2001-04-03 2012-12-31 Schering Corp Ciekla zawiesina zawierajaca przeciwgrzybiczo skuteczna ilosc posakonazolu oraz zastosowanie zmikronizowanych czastek posakonazolu
EP2141159A1 (en) * 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
WO2013036866A1 (en) 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof
WO2016087880A1 (en) * 2014-12-05 2016-06-09 Pulmocide Limited Antimycotic compound

Also Published As

Publication number Publication date
KR20220110726A (ko) 2022-08-09
CN114746415B (zh) 2025-04-11
PT4069690T (pt) 2024-12-13
LT4069690T (lt) 2025-01-10
CN114746415A (zh) 2022-07-12
JP2023505227A (ja) 2023-02-08
EP4509179A2 (en) 2025-02-19
HUE069799T2 (hu) 2025-04-28
CL2022001464A1 (es) 2023-03-24
IL293401B1 (en) 2026-08-01
MX2022006654A (es) 2022-09-07
US20260060980A1 (en) 2026-03-05
CO2022007808A2 (es) 2022-06-30
SMT202400514T1 (it) 2025-01-14
ES3000984T3 (es) 2025-03-04
SA522432879B1 (ar) 2025-01-26
EP4069690A1 (en) 2022-10-12
HRP20250042T1 (hr) 2025-03-14
US12491182B2 (en) 2025-12-09
WO2021111142A1 (en) 2021-06-10
DK4069690T3 (da) 2025-01-20
PL4069690T3 (pl) 2025-03-10
FI4069690T3 (fi) 2025-01-21
SI4069690T1 (sl) 2025-03-31
IL293401A (en) 2022-07-01
EP4069690B1 (en) 2024-11-13
AU2020397613A1 (en) 2022-06-02
CA3155829A1 (en) 2021-06-10
US20230028714A1 (en) 2023-01-26
GB201917867D0 (en) 2020-01-22
EP4509179A3 (en) 2025-02-26
RS66401B1 (sr) 2025-02-28

Similar Documents

Publication Publication Date Title
HK1253073A1 (zh) 抗真菌化合物
ECSP21088515A (es) Compuestos de pirrolidina
SA522432879B1 (ar) صور متعددة الأشكال من مركب ترايازول مضاد للفطريات pc945
PL4055021T3 (pl) Heterocykliczne związki hamujące RIP1
IL320185A (en) Heterocyclic compound
GB202216325D0 (en) Compound
CL2021000454A1 (es) Método para preparar 2-[(3r)-3--metilmofolin--4-il]-4-(1-metil-1h-pirazol-5-il)-8-(1h-pirazol-5-il)-1,7-naftiridina
IL288782B1 (en) Sustained-release alpha-ketoglutarate preparations
GB202302314D0 (en) Compound
IL284564A (en) Polymorphic forms of a modified quinoline-type bridged piperidine compound
EP3976038A4 (en) HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
GB202301239D0 (en) Compound
GB202217858D0 (en) Compound
ZA202408061B (en) Benzotriazole compound
GB202318958D0 (en) Compound
GB202304745D0 (en) Compound
GB202304355D0 (en) Compound
GB202302315D0 (en) Compound
GB202217826D0 (en) Compound
GB202217823D0 (en) Compound
GB202217852D0 (en) Compound
GB202217856D0 (en) Compound
GB202217854D0 (en) Compound
GB202217833D0 (en) Compound
GB202215117D0 (en) Compound

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]